GSK's Witty calls for an R&D renaissance

GSK CEO Andrew Witty (photo) wants everyone to know that he gets it. R&D productivity in the industry is awful, industrializing the creative process failed. And now Big Pharma has to rely on partnering with biotechs and academics to get its mojo back, recognizing that this is as much art as science. Pharma companies, meanwhile, will have to do more deals like Viiv Healthcare, which pooled its HIV products and pipelines with Pfizer. That's Witty's bottom line in an editorial he wrote for the Economist. Column

Suggested Articles

Cannabidiol might work as a powerful antibiotic against certain drug-resistant bacteria such as methicillin-resistant S. aureus.

Krystal Biotech posted data from a phase 2 study showing its topical gene therapy closed the majority of wounds in patients with a rare skin disorder.

OnKure's HDAC inhibitor overcame resistance to anti-PD-1 therapy in mouse models of B-cell lymphoma, University of Colorado researchers found.